{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:56:58Z","timestamp":1794553018881,"version":"4.9.1"},"reference-count":38,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"unspecified","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2025,2,7]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Oral glucocorticoids (OCS) remain one of the most important treatments for SLE but are associated with damage. Evidence regarding the real-world use of OCS in nationwide SLE populations is currently lacking. The aim of this study was to analyse OCS use and SLE treatments in French patients with SLE at the national level.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The nationwide French health insurance claims database, which contains pseudonymised data for \u224866 million people, was used. Prevalent patients with SLE (International Classification of Diseases, 10th Revision code M32, recorded as a chronic condition or associated with hospital stay) were identified over the year 2019. SLE treatments were captured through actual drug deliveries by pharmacies and mean daily OCS doses (prednisone equivalent) were calculated for the year 2019.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The 2019 French prevalent SLE population comprised 31\u2009852 patients (86.3% of women, with a mean age of 49.7 (\u00b115.9) years) with a mean disease duration of 7.1 (\u00b16.2) years. Among these, 48.3% were treated with OCS. The mean daily OCS dose was \u22645\u2009mg\/day in 35.9%, more than 5 mg but &lt;7.5\u2009mg\/day in 6.4% and \u22657.5\u2009mg\/day in 6.0%. The use of other SLE treatments was significantly increased in patients with higher doses of OCS (p&lt;0.0001). Potential complications of OCS, including cardiovascular diseases, infections and osteoporosis, were significantly increased in patients with SLE receiving more than 5 mg of OCS per day (p&lt;0.0001, for all). Strikingly, 13.6% of patients receiving mean daily OCS doses &gt;5\u2009mg\/day were not treated with antimalarial, immunosuppressant or biologic drugs for SLE.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In total, 48.2% of French patients with SLE were treated with OCS in 2019, including 12.4% at a mean dose &gt;5\u2009mg\/day, with an increased risk of OCS complications and a limited use of antimalarials, immunosuppressants or biologics. These results highlight the urgent need for the implementation of more robust OCS-sparing strategies in SLE.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/lupus-2024-001428","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T12:26:18Z","timestamp":1739881578000},"page":"e001428","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Real-world oral glucocorticoid use in SLE: a nation-wide population-based study using the French medico-administrative (SNDS) claim database"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8077-8394","authenticated-orcid":false,"given":"Laurent","family":"Arnaud","sequence":"first","affiliation":[{"name":"Service de Rhumatologie, H\u00f4pitaux Universitaires de Strasbourg, Centre National de R\u00e9f\u00e9rence des Maladies Syst\u00e9miques Auto-immunes Rares Est Sud-Ouest, INSERM UMRS-1109, Universit\u00e9 de Strasbourg, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Fabry-Vendrand","sequence":"additional","affiliation":[{"name":"AstraZeneca, Tour Carpe Diem, Courbevoie, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remus","family":"Todea","sequence":"additional","affiliation":[{"name":"AstraZeneca, Tour Carpe Diem, Courbevoie, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blandine","family":"Vidal","sequence":"additional","affiliation":[{"name":"AstraZeneca, Tour Carpe Diem, Courbevoie, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Cottin","sequence":"additional","affiliation":[{"name":"CEMKA, Bourg-La-Reine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Bureau","sequence":"additional","affiliation":[{"name":"CEMKA, Bourg-La-Reine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Bou\u00e9e","sequence":"additional","affiliation":[{"name":"CEMKA, Bourg-La-Reine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Thabut","sequence":"additional","affiliation":[{"name":"AstraZeneca, Tour Carpe Diem, Courbevoie, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"2025091512083013000_12.1.e001428.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30237-5"},{"key":"2025091512083013000_12.1.e001428.2","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.622225","article-title":"The Use of Glucocorticoids in Lupus Nephritis: New Pathways for an Old Drug","volume":"8","author":"Mej\u00eda-Vilet","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025091512083013000_12.1.e001428.3","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9092709","article-title":"Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues","volume":"9","author":"Porta","year":"2020","journal-title":"J Clin Med"},{"key":"2025091512083013000_12.1.e001428.4","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000590","article-title":"Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies","volume":"8","author":"Ugarte-Gil","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2025091512083013000_12.1.e001428.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390303"},{"key":"2025091512083013000_12.1.e001428.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"2025091512083013000_12.1.e001428.7","unstructured":"Assurance Maladie . M\u00e9thodologie m\u00e9dicale de la cartographie des pathologies et des d\u00e9penses, version g9 (ann\u00e9es 2015 \u00e0 2020, tous r\u00e9gimes). 2022. Available: https:\/\/assurance-maladie.ameli.fr\/sites\/default\/files\/2022_methode-reperage-pathologies_cartographie_0.pdf"},{"key":"2025091512083013000_12.1.e001428.8","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1499"},{"key":"2025091512083013000_12.1.e001428.9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00296-014-3129-5","article-title":"Risk factors for cataracts in systemic lupus erythematosus (SLE)","volume":"35","author":"Alderaan","year":"2015","journal-title":"Rheumatol Int"},{"key":"2025091512083013000_12.1.e001428.10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12916-016-0673-8","article-title":"Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis","volume":"14","author":"Singh","year":"2016","journal-title":"BMC Med"},{"key":"2025091512083013000_12.1.e001428.11","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00198-019-04906-x","article-title":"Glucocorticoid-induced osteoporosis: 2019 concise clinical review","volume":"30","author":"Adami","year":"2019","journal-title":"Osteoporos Int"},{"key":"2025091512083013000_12.1.e001428.12","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.526","article-title":"Glucocorticoid-induced osteonecrosis in systemic lupus erythematosus patients","volume":"11","author":"Kaneko","year":"2021","journal-title":"Clin Transl Med"},{"key":"2025091512083013000_12.1.e001428.13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170837"},{"key":"2025091512083013000_12.1.e001428.14","doi-asserted-by":"publisher","DOI":"10.1210\/en.2004-0037"},{"key":"2025091512083013000_12.1.e001428.15","first-page":"709","article-title":"The risk of cardiovascular morbidity and cardiovascular mortality in systemic lupus erythematosus and lupus nephritis: a Danish nationwide population-based cohort study","volume":"56","author":"Hermansen","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2025091512083013000_12.1.e001428.16","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"2025091512083013000_12.1.e001428.17","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000471"},{"key":"2025091512083013000_12.1.e001428.18","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160900"},{"key":"2025091512083013000_12.1.e001428.19","unstructured":"Agence Technique de l\u2019information sur l\u2019hospitalisation (ATIH), Available: https:\/\/www.scansante.fr\/applications\/enc-mco [Accessed 14 Dec 2024]."},{"key":"2025091512083013000_12.1.e001428.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.34672"},{"key":"2025091512083013000_12.1.e001428.21","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080828"},{"key":"2025091512083013000_12.1.e001428.22","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O"},{"key":"2025091512083013000_12.1.e001428.23","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2014-000066","article-title":"Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort","volume":"2","author":"Al Sawah","year":"2015","journal-title":"Lupus Sci Med"},{"key":"2025091512083013000_12.1.e001428.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2013.03.001"},{"key":"2025091512083013000_12.1.e001428.25","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/acr2.11550","article-title":"Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study","volume":"5","author":"DerSarkissian","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"2025091512083013000_12.1.e001428.26","doi-asserted-by":"crossref","DOI":"10.1093\/rap\/rkab061","article-title":"Disease severity, flares and treatment patterns in adults with systemic lupus erythematosus in the UK: a real-world observational retrospective cohort analysis","volume":"5","author":"Langham","year":"2021","journal-title":"Rheumatol Adv Pract"},{"key":"2025091512083013000_12.1.e001428.27","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1007\/s10067-023-06681-x","article-title":"Burden of disease and real-world treatment patterns of patients with systemic lupus erythematosus in the Australian OPAL dataset","volume":"42","author":"Ciciriello","year":"2023","journal-title":"Clin Rheumatol"},{"key":"2025091512083013000_12.1.e001428.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.09.011"},{"key":"2025091512083013000_12.1.e001428.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.09.009"},{"key":"2025091512083013000_12.1.e001428.30","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/acr.22574","article-title":"Glucocorticoid Use in Patients With Systemic Lupus Erythematosus: Association Between Dose and Health Care Utilization and Costs","volume":"67","author":"Chen","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025091512083013000_12.1.e001428.31","first-page":"1799","article-title":"Healthcare resource utilization and costs associated with long-term corticosteroid exposure in patients with systemic lupus erythematosus","volume":"27","author":"Kabadi","year":"2018","journal-title":"Lupus (Los Angel)"},{"key":"2025091512083013000_12.1.e001428.32","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.clinthera.2023.04.013","article-title":"Health Care Costs With Sustained Oral Corticosteroid Use in Systemic Lupus Erythematosus","volume":"45","author":"Huang","year":"2023","journal-title":"Clin Ther"},{"key":"2025091512083013000_12.1.e001428.33","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s40744-023-00566-w","article-title":"Adverse Outcomes, Healthcare Resource Utilization, and Costs Associated with Systemic Corticosteroid use Among Adults with Systemic Lupus Erythematosus in the UK","volume":"10","author":"Stirnadel-Farrant","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2025091512083013000_12.1.e001428.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.08.034"},{"key":"2025091512083013000_12.1.e001428.35","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000526","article-title":"Comorbidity and healthcare utilisation in persons with incident systemic lupus erythematosus followed for 3 years after diagnosis: analysis of a claims data cohort","volume":"8","author":"Albrecht","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2025091512083013000_12.1.e001428.36","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1678170"},{"key":"2025091512083013000_12.1.e001428.37","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000446","article-title":"Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre","volume":"8","author":"Hill","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2025091512083013000_12.1.e001428.38","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000153","article-title":"First month prednisone dose predicts prednisone burden during the following 11\u2005months: an observational study from the RELES cohort","volume":"3","author":"Ruiz-Irastorza","year":"2016","journal-title":"Lupus Sci Med"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2024-001428","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T19:08:40Z","timestamp":1757963320000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2024-001428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2,18]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/lupus-2024-001428"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2024-001428","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}